Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Feb;66(2):240-50.
doi: 10.1093/jac/dkq447. Epub 2010 Nov 30.

Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection

Peter L Anderson  1 , Jennifer J Kiser, Edward M Gardner, Joseph E Rower, Amie Meditz, Robert M Grant
Affiliations
Review

Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection

Peter L Anderson et al. J Antimicrob Chemother. 2011 Feb.

Abstract

The use of antiretroviral medications in HIV-negative individuals as pre-exposure prophylaxis (PrEP) is a promising approach to prevent HIV infection. Tenofovir disoproxil fumarate (TDF) and emtricitabine exhibit desirable properties for PrEP including: favourable pharmacokinetics that support infrequent dosing; few major drug-drug or drug-food interactions; an excellent clinical safety record; and pre-clinical evidence for efficacy. Several large, randomized, controlled clinical trials are evaluating the safety and efficacy of TDF and emtricitabine for this new indication. A thorough understanding of variability in drug response will help determine future investigations in the field and/or implementation into clinical care. Because tenofovir and emtricitabine are nucleos(t)ide analogues, the HIV prevention and toxicity effects depend on the triphosphate analogue formed intracellularly. This review identifies important cellular pharmacology considerations for tenofovir and emtricitabine, which include drug penetration into relevant tissues and cell types, race/ethnicity/pharmacogenetics, gender, cellular activation state and appropriate episodic or alternative dosing strategies based on pharmacokinetic principles. The current state of knowledge in these areas is summarized and the future utility of intracellular pharmacokinetics/pharmacodynamics for the PrEP field is discussed.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Summary of the intracellular disposition of tenofovir and emtricitabine including the transporters and enzymes responsible for the production of tenofovir-DP and emtricitabine-TP. mDNC, mitochondrial deoxynucleotide carrier; 3PGK, 3′-phosphoglycerate kinase; NDPK, nucleotide diphosphate kinase; 5′NT, cytosolic 5′-nucleotidase; dCK, deoxycytidine kinase; dCMK, uridylate-cytidylate kinase; OAT-1 & -3, organic anion transporter 1 & 3; OCT-1 & -2, organic cation transporter 1 & 2; CNT 1, concentrative nucleoside transporter 1; ENT 2, equilibrative nucleoside transporter 2; MRP 1 & 4 & 5, multidrug resistance protein 1 & 4 & 5; BCRP, breast cancer resistance protein; AK, adenylate kinase; dATP, 2′-deoxyadenosine-triphosphate; dCTP, 2′-deoxycytidine-triphosphate; TFV, tenofovir; FTC, emtricitabine; MP, monophosphate; DP, diphosphate; TP, triphosphate.
Figure 2.
Figure 2.
Half-lives for intracellular triphosphates (TPs) (top bars) and plasma (bottom bars) for tenofovir (TFV), emtricitabine (FTC), didanosine (ddI), lamivudine (3TC), abacavir (ABC), zidovudine (ZDV) and stavudine (d4T). Note, the intracellular triphosphate for didanosine is dideoxyadenosine-TP and that for abacavir is carbovir-TP. QD, once daily.
Figure 3.
Figure 3.
Predicted tenofovir (TFV)-DP accumulation to steady state in humans with three different dosing strategies: daily TDF (QD); TDF every three days (Q3D); and weekly TDF (Q7D). See text for parameters used for simulation.
Figure 4.
Figure 4.
Theoretical concentration-effect profile for tenofovir (TFV) and emtricitabine (FTC) for HIV prevention, including potential sources of pharmacokinetic–pharmacodynamic variability. The sigmoid curves define the main drug effects of HIV prevention and toxicity. The horizontal arrows represent factors that influence the positions of the curves and the horizontal arrow on the x-axis represents factors that influence the intracellular drug and endogenous nucleotides. Identified sources of variability are discussed in the text.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. UNAIDS. 09 AIDS Epidemic Update. November 2009. http://data.unaids.org/pub/Report/2009/2009_epidemic_update_en.pdf. (15 March 2010, date last accessed)
    1. Rotheram-Borus MJ, Swendeman D, Chovnick G. The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol. 2009;5:143–67. - PMC - PubMed
    1. Dolin R. HIV vaccine trial results—an opening for further research. N Engl J Med. 2009;361:2279–80. - PubMed
    1. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146:591–601. - PubMed
    1. Garcia-Lerma JG, Paxton L, Kilmarx PH, et al. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci. 2010;31:74–81. - PubMed

Publication types